{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/eczema-atopic/prescribing-information/topical-antibiotics-antiseptics/","result":{"pageContext":{"chapter":{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics","depth":2,"htmlHeader":"<!-- begin field 32b79401-3504-4d80-bf42-07b1dc373c73 --><h2>Topical antibiotics and antiseptics</h2><!-- end field 32b79401-3504-4d80-bf42-07b1dc373c73 -->","summary":"","htmlStringContent":"<!-- begin item ff304a1a-273b-458f-a5a7-83cae3daf83f --><!-- end item ff304a1a-273b-458f-a5a7-83cae3daf83f -->","topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","lastRevised":"Last revised in January 2021","chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","fullItemName":"Management","slug":"management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"30190afe-aca4-5fac-b73a-68301f6ce160","slug":"prescribing-issues","fullItemName":"Prescribing issues","depth":3,"htmlHeader":"<!-- begin field 9556e344-2f85-401a-9bae-7487912ca096 --><h3>What do I need to know about prescribing topical antiseptics and antibiotics?</h3><!-- end field 9556e344-2f85-401a-9bae-7487912ca096 -->","summary":"","htmlStringContent":"<!-- begin item 55961fe1-c9a2-4187-9ec2-636809c43714 --><!-- begin field c4ffe0e9-5af2-4a5b-8af8-9f2ac1179c46 --><ul><li><strong>Antiseptics are used to lower bacterial load. </strong>They include solutions of chlorhexidine salts and triclosan, potassium permanganate, and antiseptics incorporated into emollients. </li><li><strong>A range of topical antiseptics and antibiotics are available,</strong> either alone or combined with emollients or topical corticosteroids. See Table 3 for more information. </li><li><strong>If a topical antibiotic alone is prescribed,</strong> continue treatment with a topical corticosteroid.<ul><li>Avoid using combined corticosteroid/antibiotic preparations (such as Fucibet® cream) on a regular basis as this will increase the risk of antibiotic resistance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>].</li><li>If prescribing combined products, generally the same issues and precautions apply as with topical corticosteroids alone. However, sensitization is more likely to occur because of the inclusion of more additives.</li></ul></li></ul><p><strong>Table 3</strong><strong>. </strong>Available topical antibiotic, combined antibiotic/corticosteroid, and antiseptic/corticosteroid products available for treating eczema.</p><table><thead><tr><th colspan=\"1\"><p>Product type</p></th><th colspan=\"1\"><p>Active components</p></th><th colspan=\"1\"><p>Formulation (s)</p></th><th colspan=\"1\"><p>Proprietary name</p></th></tr></thead><tbody><tr><td colspan=\"1\">Topical antibiotic alone</td><td colspan=\"1\">Mupirocin</td><td colspan=\"1\">Cream and ointment</td><td colspan=\"1\">Bactroban®</td></tr><tr><td colspan=\"1\">Fusidic acid</td><td colspan=\"1\">Cream and ointment</td><td colspan=\"1\">Fucidin®</td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\">Topical antibiotic combined with corticosteroid</td><td colspan=\"1\">Fusidic acid and hydrocortisone</td><td colspan=\"1\">Cream and ointment</td><td colspan=\"1\">Fucidin H®</td></tr><tr><td colspan=\"1\">Chlorquinaldol and hydrocortisone butyrate</td><td colspan=\"1\">Cream and ointment</td><td colspan=\"1\">Locoid C®</td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\">Clioquinol and betamethasone valerate</td><td colspan=\"1\">Cream and ointment</td><td colspan=\"1\">Betnovate-C®</td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\">Neomycin and betamethasone valerate</td><td colspan=\"1\">Cream and ointment</td><td colspan=\"1\">Betnovate-N®</td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\">Fusidic acid and betamethasone valerate</td><td colspan=\"1\">Cream</td><td colspan=\"1\">Fucibet®</td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\">Clioquinol and fluocinolone acetonide</td><td colspan=\"1\">Cream and ointment</td><td colspan=\"1\">Synalar-C®</td><td colspan=\"1\"> </td></tr><tr><td colspan=\"1\">Chlortetracycline and triamcinolone acetonide</td><td colspan=\"1\">Ointment</td><td colspan=\"1\">Aureocort®</td><td colspan=\"1\"> </td></tr><tr><td colspan=\"4\"><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF 72, 2016</a>]</td></tr></tbody></table><!-- end field c4ffe0e9-5af2-4a5b-8af8-9f2ac1179c46 --><!-- end item 55961fe1-c9a2-4187-9ec2-636809c43714 -->","subChapters":[]},{"id":"6f88ec50-a82f-524e-910a-cfd5ac95c3cf","slug":"usage-instructions","fullItemName":"Usage instructions","depth":3,"htmlHeader":"<!-- begin field c3b3875b-c4bb-4649-aed1-e8cac647c532 --><h3>What should I advise on how to use a topical antibiotic or antiseptic?</h3><!-- end field c3b3875b-c4bb-4649-aed1-e8cac647c532 -->","summary":"","htmlStringContent":"<!-- begin item f51dfd68-abb8-4cb2-abbc-ff5bdd770815 --><!-- begin field e179767a-ae46-4a14-ae86-61c945924cb2 --><ul><li><strong>Advise the person:</strong><ul><li>Not to use topical antibiotics for more than 2 weeks (due to the increased risk of sensitization and bacterial resistance).</li><li>That if their skin worsens during treatment, they should stop using the product and seek medical advice.<ul><li>This may be a sign of sensitization or an indication that the product is not effectively treating the infection.</li><li>Oral antibiotics may be required.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>]</p><!-- end field e179767a-ae46-4a14-ae86-61c945924cb2 --><!-- end item f51dfd68-abb8-4cb2-abbc-ff5bdd770815 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}